Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer

Table 1

Association between PRDX expression and OS in GC patients at different clinical stages.

PRDXs	Clinical stages	Cases	Low	High	HR (95% CI)	value
PRDX1	I	67	34	33	0.51 (0.17–1.52)	0.217
	II	140	70	70	0.80 (0.43–1.46)	0.462
	III	315	152	153	0.53 (0.40–0.71)	<0.001
	IV	148	74	74	0.57 (0.39–0.84)	0.004
PRDX2	I	67	34	33	1.15 (0.43–3.08)	0.787
	II	140	70	70	0.79 (0.43–1.44)	0.439
	III	315	152	153	0.53 (0.40–0.71)	<0.001
	IV	148	74	74	0.79 (0.54–1.15)	0.219
PRDX3	I	67	34	33	0.51 (0.17–1.52)	0.218
	II	140	70	70	0.79 (0.43–1.44)	0.749
	III	315	152	153	0.62 (0.46–0.82)	<0.001
	IV	148	74	74	0.86 (0.58–1.25)	0.425
PRDX4	I	67	34	33	0.75 (0.28–2.03)	0.571
	II	140	70	70	0.94 (0.51–1.72)	0.836
	III	315	152	153	0.67 (0.50–0.89)	0.005
	IV	148	74	74	0.66 (0.45–0.96)	0.031
PRDX5	I	62	31	31	0.93 (0.31–2.78)	0.897
	II	135	68	67	1.41 (0.74–2.68)	0.294
	III	197	98	99	1.03 (0.71–1.50)	0.866
	IV	140	70	70	0.92 (0.62–1.36)	0.660
PRDX6	I	67	34	33	0.63 (0.23–1.74)	0.367
	II	140	70	70	0.92 (0.51–1.67)	0.787
	III	315	152	153	0.72 (0.54–0.96)	0.025
	IV	148	74	74	0.90 (0.62–1.32)	0.607